Silence Therapeutics (SLN) Payables: 2019-2024
Historic Payables for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $16.4 million.
- Silence Therapeutics' Payables rose 191.64% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 191.64%. This contributed to the annual value of $16.4 million for FY2024, which is 5.55% up from last year.
- According to the latest figures from FY2024, Silence Therapeutics' Payables is $16.4 million, which was up 5.55% from $15.5 million recorded in FY2023.
- Silence Therapeutics' 5-year Payables high stood at $16.4 million for FY2024, and its period low was $10.5 million during FY2020.
- Its 3-year average for Payables is $15.9 million, with a median of $15.6 million in 2022.
- As far as peak fluctuations go, Silence Therapeutics' Payables surged by 41.03% in 2021, and later fell by 0.62% in 2023.
- Silence Therapeutics' Payables (MRY) stood at $10.5 million in 2020, then soared by 41.03% to $14.8 million in 2021, then rose by 5.38% to $15.6 million in 2022, then decreased by 0.62% to $15.5 million in 2023, then rose by 5.55% to $16.4 million in 2024.
- Its Payables was $16.4 million in FY2024, compared to $15.5 million in FY2023 and $15.6 million in FY2022.